Par Non Current Liabilities Other from 2010 to 2024

PAR Stock   290.40  11.35  4.07%   
Par Drugs' Non Current Liabilities Other is decreasing over the years with slightly volatile fluctuation. Overall, Non Current Liabilities Other is expected to go to 1,333 this year. During the period from 2010 to 2024 Par Drugs Non Current Liabilities Other annual values regression line had geometric mean of  1,819 and mean square error of  310,434. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2010-12-31
Previous Quarter
900
Current Value
1.3 K
Quarterly Volatility
K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Par Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Par Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 M, Total Revenue of 669.2 M or Gross Profit of 640.4 M, as well as many indicators such as . Par financial statements analysis is a perfect complement when working with Par Drugs Valuation or Volatility modules.
  
This module can also supplement various Par Drugs Technical models . Check out the analysis of Par Drugs Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.